Markus K H Wiedmann1, Cathrine Brunborg1, Antonio Di Ieva1, Kristina Lindemann1, Tom B Johannesen1, Lars Vatten1, Eirik Helseth1, John A Zwart1. 1. Department of Neurosurgery, Oslo University Hospital, Oslo, Norway; Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Oslo, Norway; Neurosurgery Unit, Faculty of Medicine and Health Sciences, Macquarie University, Sydney,Australia; Crown Princess Mary Cancer Care Centre, Westmead Hospital, Sydney,Australia; NHMRC Clinical Trials Centre, Sydney,Australia; Department of Gynecological Cancer, Oslo University Hospital (Norwegian Radium Hospital), Oslo, Norway; The Cancer Registry of Norway, Oslo, Norway; Department of Public Health, Norwegian University of Science and Technology, Trondheim, Norway; FORMI and Department of Neurology, Oslo University Hospital (Ulleval),Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway.
Abstract
BACKGROUND: Glioma comprises a heterogeneous group of mostly malignant brain tumors, whereof glioblastoma (GBM) represents the largest and most lethal subgroup. Body height and body mass index (BMI) are risk factors for other cancers, but no previous study has examined anthropometric data in relation to different glioma subgroups. METHODS: This prospective cohort study includes 1.8 million Norwegian women and men between ages 14 and 80 years at baseline. Body weight and height were measured, and incident cases of glioma were identified by linkage to the National Cancer Registry. Cox regression analyses were performed to evaluate risk for different glioma subgroups in relation to anthropometric measures. RESULTS: During 54 million person-years of follow-up, 4,382 gliomas were identified. Overweight and obesity were not associated with risk for any glioma subgroup. Height was positively associated with risk for GBM and all other gliomas (hazard ratio [HR] per 10 cm increase: 1.24; 95% confidence interval [CI], 1.17-1.31 and 1.18; 95% CI, 1.09-1.29) but not with the proxy for isocitrate dehydrogenase (IDH)-mutant glioma (HR, 1.09; 95% CI, 0.98-1.21). In further subgroup analyses, the effect of height on glioma risk varied significantly with positive associations for oligoastrocytoma (HR, 1.74; 95% CI, 1.20-2.53) and malignant glioma not otherwise specified (NOS) (HR, 1.42; 95% CI, 1.16-1.76, but not with diffuse astrocytoma (WHO grades II and III) or oligodendroglioma. CONCLUSION: This epidemiologic study consolidates height as a risk factor for GBM and other gliomas. It further indicates that this association is not universal for gliomas but may differ between different glioma subgroups.
BACKGROUND: Glioma comprises a heterogeneous group of mostly malignant brain tumors, whereof glioblastoma (GBM) represents the largest and most lethal subgroup. Body height and body mass index (BMI) are risk factors for other cancers, but no previous study has examined anthropometric data in relation to different glioma subgroups. METHODS: This prospective cohort study includes 1.8 million Norwegian women and men between ages 14 and 80 years at baseline. Body weight and height were measured, and incident cases of glioma were identified by linkage to the National Cancer Registry. Cox regression analyses were performed to evaluate risk for different glioma subgroups in relation to anthropometric measures. RESULTS: During 54 million person-years of follow-up, 4,382 gliomas were identified. Overweight and obesity were not associated with risk for any glioma subgroup. Height was positively associated with risk for GBM and all other gliomas (hazard ratio [HR] per 10 cm increase: 1.24; 95% confidence interval [CI], 1.17-1.31 and 1.18; 95% CI, 1.09-1.29) but not with the proxy for isocitrate dehydrogenase (IDH)-mutant glioma (HR, 1.09; 95% CI, 0.98-1.21). In further subgroup analyses, the effect of height on glioma risk varied significantly with positive associations for oligoastrocytoma (HR, 1.74; 95% CI, 1.20-2.53) and malignant glioma not otherwise specified (NOS) (HR, 1.42; 95% CI, 1.16-1.76, but not with diffuse astrocytoma (WHO grades II and III) or oligodendroglioma. CONCLUSION: This epidemiologic study consolidates height as a risk factor for GBM and other gliomas. It further indicates that this association is not universal for gliomas but may differ between different glioma subgroups.
Authors: Quinn T Ostrom; Luc Bauchet; Faith G Davis; Isabelle Deltour; James L Fisher; Chelsea Eastman Langer; Melike Pekmezci; Judith A Schwartzbaum; Michelle C Turner; Kyle M Walsh; Margaret R Wrensch; Jill S Barnholtz-Sloan Journal: Neuro Oncol Date: 2014-07 Impact factor: 12.300
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316
Authors: Cari M Kitahara; Michael Gamborg; Preetha Rajaraman; Thorkild I A Sørensen; Jennifer L Baker Journal: Am J Epidemiol Date: 2014-09-09 Impact factor: 4.897
Authors: Steven C Moore; Preetha Rajaraman; Robert Dubrow; Amy S Darefsky; Corinna Koebnick; Albert Hollenbeck; Arthur Schatzkin; Michael F Leitzmann Journal: Cancer Res Date: 2009-10-06 Impact factor: 12.701
Authors: M Wiedmann; C Brunborg; K Lindemann; T B Johannesen; L Vatten; E Helseth; J A Zwart Journal: Br J Cancer Date: 2013-06-18 Impact factor: 7.640
Authors: Jessica Tyrrell; Samuel E Jones; Robin Beaumont; Christina M Astley; Rebecca Lovell; Hanieh Yaghootkar; Marcus Tuke; Katherine S Ruth; Rachel M Freathy; Joel N Hirschhorn; Andrew R Wood; Anna Murray; Michael N Weedon; Timothy M Frayling Journal: BMJ Date: 2016-03-08
Authors: Jon Foss-Skiftesvik; Christian Munch Hagen; René Mathiasen; Dea Adamsen; Marie Bækvad-Hansen; Anders D Børglum; Merete Nordentoft; Thomas Werge; Michael Christiansen; Kjeld Schmiegelow; Marianne Juhler; Preben Bo Mortensen; David Michael Hougaard; Jonas Bybjerg-Grauholm Journal: Childs Nerv Syst Date: 2020-11-23 Impact factor: 1.475
Authors: Quinn T Ostrom; Maral Adel Fahmideh; David J Cote; Ivo S Muskens; Jeremy M Schraw; Michael E Scheurer; Melissa L Bondy Journal: Neuro Oncol Date: 2019-11-04 Impact factor: 12.300
Authors: David J Cote; Mary K Downer; Timothy R Smith; Stephanie A Smith-Warner; Kathleen M Egan; Meir J Stampfer Journal: Cancer Causes Control Date: 2018-06-26 Impact factor: 2.506
Authors: Lisa R Rogers; Quinn T Ostrom; Julia Schroer; Jaime Vengoechea; Li Li; Stanton Gerson; Charles J Nock; Mitchell Machtay; Warren Selman; Simon Lo; Andrew E Sloan; Jill S Barnholtz-Sloan Journal: Neurooncol Pract Date: 2020-03-31